Impact of pramipexole on the onset of levodopa-related dyskinesias.
Dyskinesias are a major complication of dopaminergic therapy in the long-term treatment of Parkinson's disease. In the CALM-PD trial, subjects were initially randomized to levodopa or pramipexole and could later add levodopa if needed. After adjusting for disease duration and daily levodopa dosage, the incidence of dyskinesias after initiating levodopa was not significantly different among subjects initially randomized to levodopa and those initially randomized to pramipexole.
Constantinescu
Radu
R
Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA. radu.constantinescu@vgregion.se
Romer
Megan
M
McDermott
Michael P
MP
Kamp
Cornelia
C
Kieburtz
Karl
K
D000368:Aged; D017109:Akathisia, Drug-Induced / Q000209:etiology*; D000978:Antiparkinson Agents / Q000009:adverse effects*; D052160:Benzothiazoles / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy; D000077487:Pramipexole; D011336:Probability
D000978:Antiparkinson Agents; D052160:Benzothiazoles; D007980:Levodopa; D000077487:Pramipexole